Phio Pharmaceuticals Corp Stock Price, News & Analysis

Phio Pharmaceuticals (NASDAQ: PHIO) presented promising new data on its lead product candidate, PH-762, at the SITC 36th Annual Meeting. The study indicates that local administration of PH-762 in a hepatocarcinoma model not only inhibits the growth of treated tumors but also clears untreated distal tumors, suggesting a systemic immune response. Results showed that 80% of untreated tumors were completely cured, highlighting PH-762's potential as a new immunotherapy option with reduced systemic toxicity compared to traditional therapies. This data supports plans for a Phase 1 clinical trial in melanoma patients.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its Q3 2021 financial results, reporting a net loss of $3.7 million or $0.28 per share, an increase from $2.3 million or $0.40 per share for Q3 2020. Cash and cash equivalents stood at $26.5 million as of September 30, 2021, expected to last until Q2 2023. The company aims to commence its first-in-human trial for PH-762 in Q1 2022 and expects to file a clinical trial application for PH-894 in H2 2022, showcasing the potential of its INTASYL technology in immuno-oncology.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that new data indicates a systemic immune response can be triggered by its lead product candidate, PH-762, after local administration. These findings will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C. from November 10-14, 2021. The relevant poster presentation is scheduled for November 12, 2021, at 7:00 am ET, showcasing potential advancements in immuno-oncology therapy.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced significant findings at the AACR-NCI-EORTC conference on October 7, 2021, regarding PH-894, its self-delivering RNAi compound targeting BRD4. The results indicate that PH-894 effectively silenced BRD4, enhancing T cell activation and tumor growth inhibition in vivo. This suggests PH-894 may serve as a promising immunotherapy option by reprogramming T cells. Phio is currently working on IND-enabling studies to advance PH-894 into clinical trials.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company specializing in immuno-oncology, announced two significant poster presentations at upcoming scientific conferences in October 2021. The first will occur at the AACR-NCI-EORTC Virtual International Conference from October 7-10, showcasing research on targeting BRD4 in T cells with self-delivering RNAi PH-894. The second presentation at the 8th Immunotherapy of Cancer Conference (ITOC8) on October 8-9 will focus on optimizing T lymphocytes for solid tumor therapy. For more details, visit their website.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced promising results from a study showcased at the ESMO Congress 2021. The study demonstrated that the INTASYL technology could cure tumors and elicit durable systemic immunity in a preclinical model targeting PD-1 and BRD4. Specifically, 83% of the treated animals showed complete tumor response, even with low dosage therapy. This research highlights INTASYL's potential as a versatile immuno-oncology therapeutic platform, with further clinical trials anticipated to validate its efficacy.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13 to 15, 2021. Dr. Gerrit Dispersyn, President & CEO, will present on September 13 at 7:00 AM ET. A webcast of the presentation will be available, with replays accessible on the company's website for 90 days. Phio focuses on developing immuno-oncology therapeutics using its proprietary INTASYL platform, aimed at enhancing immune response against tumors.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced that it will present new clinical study data at the ESMO Virtual Congress 2021 from September 16-21, 2021. The presentation will focus on dual targeting PD-1 and BRD4 using the company's proprietary INTASYL self-delivering RNAi platform, aiming to elicit persistent anti-tumor immunity following tumor resolution. The abstract number for this presentation is #4154. Archived details will be available on the Company's website in the Investors section.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q2 2021, showing a net loss of $2.7 million. The company has $29.4 million in cash, sufficient to fund operations through Q2 2023. Phio is advancing its INTASYL™ platform, with promising preclinical data for its lead asset, PH-762, aimed at PD-1 in cancer treatment. Clinical trials are set to begin in 2022, with expected milestones including first-in-human studies for melanoma. R&D expenses increased to $1.7 million, reflecting expanded clinical preparation.